SOURCE: Medpace


September 16, 2014 10:58 ET

Medpace Continues to Expand Therapeutic Leadership in Oncology Drug Development

Dr. Franklin O. Smith Joins Medpace as Vice President Medical Affairs for Oncology

CINCINNATI, OH--(Marketwired - Sep 16, 2014) - Dr. Franklin O. Smith, III, MD has joined Medpace as Vice President Medical Affairs for oncology clinical research. Medpace, a global drug and medical device Clinical Research Organization (CRO), is known for its strong therapeutic and regulatory expertise across key therapeutic areas including oncology. Dr. Smith is an industry leader in hematologic malignancies, stem cell transplantation, bone marrow failure syndromes, and childhood cancers. In addition to being a pioneer in hematologic oncology and cord blood transplantation, he is highly-regarded author, speaker, and industry participant. With the addition of Dr. Smith, Medpace further strengthens its oncology drug development capabilities across the full range of solid and hematologic malignancies, as well as specialties in pediatric and rare disease. 

About Dr. Franklin O. Smith, III, MD
Dr. Frank Smith received his MD degree from the University of South Carolina School of Medicine and completed post-doctoral training in pediatrics at the University of Florida and fellowship training in pediatric hematology/oncology at the University of Washington and the Fred Hutchinson Cancer Research Center. Prior to joining Medpace, Dr. Smith was instrumental in helping build two prestigious stem cell transplant programs at both the University of Cincinnati Cancer Institute and at Riley Hospital for Children at Indiana University. He also was the Director, Division of Hematology/Oncology at Cincinnati Children's Hospital Medical Center and Vice-Chair of the Children's Oncology Group. He is an adjunct Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine, and has had over 150 scientific manuscripts published in medical and scientific journals. Dr. Smith is active with various national and international committees and societies in the field of research and clinical care, including serving on the local and national boards of the Leukemia and Lymphoma Society, Chair of the Board of Managers for the Foundation for the Accreditation of Cellular Therapy (FACT) Consulting Services, faculty for the ASCO/AACR Clinical Cancer Research Workshop and as a member of the NCI's Central Institutional Review Board. Dr. Smith has also served on ad-hoc committees for the FDA including Special Emphasis Panels for Orphan Products Development.

Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions -- the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information visit the Medpace website at: